Cancer vaccines are designed to elicit robust, tumor-specific immune responses and have remained a cornerstone of cancer immunotherapy development for decades. The vaccine landscape encompasses a diverse range of modalities, including oncolytic viruses, gene therapies, cell therapies, personalized neoantigen vaccines, and peptide-based approaches, with development spanning multiple solid tumor indications and disease settings throughout the patient journey. While several vaccine monotherapies have demonstrated clinical efficacy and achieved regulatory approval, current development is increasingly focused on combination strategies, particularly with PD-(L)1 inhibitors, to enhance antitumor activity and improve patient outcomes.
The ONCrg Vaccine Pipeline Strategies report provides concise analyses of vaccine-based therapies in development from preclinical through approved stages, highlighting key trends, competitive dynamics, and emerging development paradigms. The report draws on intelligence spanning multiple tumor types, informed by continuous monitoring of AACR, ASCO, ESMO, and SITC, as well as relevant clinical, regulatory, and corporate developments throughout the year.
